2024-09-04 - Analysis Report
## Vertex Pharmaceuticals (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals is a biotechnology company that focuses on developing and commercializing therapies for patients with serious diseases.

**Performance Analysis:**

1. **Relative Performance:** Over the period analyzed, VRTX has outperformed the S&P 500 (VOO) by a significant margin. The cumulative return of VRTX stands at 141.66%, compared to 89.66% for VOO, resulting in a relative outperformance of 52.0%. This puts the stock's relative performance in the 91.44th percentile of its historical range, indicating a strong relative performance compared to its historical trend.

2. **Recent Price Movements:**
   * **Closing Price:** $495.89
   * **5-day Moving Average:** $488.38
   * **20-day Moving Average:** $478.45
   * **60-day Moving Average:** $482.04

   The stock price is currently trading above all three moving averages, suggesting a bullish momentum in the short to medium term.

3. **Technical Indicators:**
   * **RSI:** 79.95
   * **PPO:** 0.39
   * **Delta_Previous_Relative_Divergence:** -6.98 (Short-term downtrend)
   * **Expected Return:** 5.46% (Potential maximum return over 5 years)

   The high RSI value suggests the stock is overbought, potentially indicating an upcoming correction. The positive PPO value points towards a bullish momentum, while the negative Delta_Previous_Relative_Divergence suggests a short-term downtrend. The Expected Return of 5.46% indicates potential growth in the long term.

4. **Recent Earnings and Outlook:**

    | Date | EPS | Revenue |
    |---|---|---|
    | 2024-08-02 | -13.92 | 2.65 B$ | 
    | 2024-05-07 | 4.26 | 2.69 B$ |
    | 2023-11-07 | 4.01 | 2.48 B$ |
    | 2023-08-02 | 3.55 | 2.49 B$ |
    | 2024-08-02 | 3.55 | 2.49 B$ |

    The latest earnings report for Q2 2024 shows a significant decline in EPS, which is below analysts' expectations. This decline is likely attributed to increased research and development expenses as Vertex continues to invest in its pipeline.  

**Summary:**

VRTX has shown a strong outperformance compared to the S&P 500 in the past. The recent price movements suggest a bullish momentum, while the technical indicators point towards potential overbought conditions and a short-term downtrend. The recent earnings report indicates a decline in EPS, but Vertex remains focused on its growth strategy and investing heavily in R&D. 

**Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice. It's essential to conduct your own research and consult with a financial professional before making any investment decisions. 
